Editor's note: This story was updated at 1225p ET on Feb. 21 with comment from Eli Lilly. Several individuals enrolled in a phase 3 trial for Eli Lilly's (NYSE:LLY) next-generation obesity drug ...

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings topped ...